Market Cap 599.52M
Revenue (ttm) 23.61M
Net Income (ttm) -105.51M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -446.89%
Debt to Equity Ratio 0.52
Volume 710,400
Avg Vol 1,942,528
Day's Range N/A - N/A
Shares Out 56.14M
Stochastic %K 15%
Beta 1.49
Analysts Strong Sell
Price Target $23.71

Company Profile

Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 1/2 clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug pro...

Industry: Biotechnology
Sector: Healthcare
Phone: 321 939 3416
Website: zevra.com
Address:
1180 Celebration Boulevard, Suite 103, Celebration, United States
HuntingHighAndLow
HuntingHighAndLow Oct. 25 at 9:38 PM
$ZVRA The table below comes from the linked healthcare economics report that looks at FDA-approved drugs launched between 2022–24. The discrepancy between prescriptions written and first-time dispensed owes mainly to payer non-coverage and “utilization” delays such as prior authorization and step therapy. “On average, only 29% of total dispensed commercial new-to-brand prescriptions were ultimately successfully filled overall.” While not a marketing report, additional tables and figures feature data collected by IQVIA that I’ve seen nowhere else. https://icer.org/wp-content/uploads/2025/10/ICER_2025_Launch-Price-and-Access-Final-Report_For-Publication.pdf
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 25 at 5:49 PM
Enter: $ZVRA Calls Strike Price: $11 Expiry Date: NOV 21 2025 Buy in Price: $1.20 - $2.00 Sell Price: $1.70 Profit : +42% (Turn every $1 into $1.42) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
KemPharm_rocks
KemPharm_rocks Oct. 25 at 3:47 PM
$ZVRA Here’s my point, just in case you missed my sarcasm. Go buy your shares, sit down, and read a book. Many of us have been waiting here for over five years. And I do not say that to impress you, but to impress upon you, that it is time to relax about Zevra. The handwriting is on the wall.
2 · Reply
KemPharm_rocks
KemPharm_rocks Oct. 25 at 3:35 PM
$ZVRA “Oh, my little margin account!” Waaaa 😭! “Oh, my little call options!” Waaaa 😭! “Oh, my little put options!” Waaaa 😭! “Oh, my little warrants!” Waaaa 😭! STFU. We don’t give a flying rats ass about the shares you are swinging around with day-trading either. Wake the F up, nobody here wants to hear about it. Go complain to your therapist, see what they have to tell you.
0 · Reply
KemPharm_rocks
KemPharm_rocks Oct. 25 at 3:30 PM
$ZVRA One fortnight, which is the Old English term , meaning fourteen nights. So all you complaining weenies out there, need to keep your panties and poopie diapers on for one more fortnight. If you can’t handle that, then you do not belong here with the big boys, the little play pin is down the hallway on your right. Now GTF out of my house! 🤭
0 · Reply
jemer
jemer Oct. 25 at 3:27 PM
$ZVRA Keep reading over and over again that Migulstat/Miplyffa is the primary standard of care and Aqneursa is secondary. This Facebook Post is from NPC Awareness page. When she talks about Arimoclomol not being FDA approved, she must mean that it wasnt approved when her child was 1st diagnosed with NPC.
1 · Reply
KemPharm_rocks
KemPharm_rocks Oct. 25 at 3:18 PM
$ZVRA 10 Business Days!!! Let’s start the countdown. The world 🌎 will FINALLY have their proof, in back & white, that Zevra is among the few, the proud, and PROFITABLE small-cap biotech companies out there. No more of this “cash-runway till…” crap! Cash runway FOREVER!!!
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 25 at 2:14 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ZVRA Current Share Price: $10.70 Contracts: $ZVRA December 18, 2026 $12 Calls Scale in: $2.88- $3.52 Scale out: $4.48-$5.76 Can Easily Capture: 60% ROI Blended DTE: 421 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
KakashiFlux
KakashiFlux Oct. 25 at 1:40 AM
0 · Reply
WaynD01
WaynD01 Oct. 24 at 11:58 PM
$ZVRA To every one’s surprise the short interest is down by 1M ahares. If you were following the short interest history very closely you will realize that it was an unprofitable trade for them. They were shorting this in single digits all the time and it was in 2 digits in all the reporting period . So why they decided to cover for a loss? 1) Great Q3 earnings, 2) Buyout 3) scared of a short squeeze, etc Also we see they have changed their MO of waking down the price. All these makes me more optimistic.
0 · Reply
Latest News on ZVRA
Zevra Therapeutics, Inc. (ZVRA) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 8:43 PM EDT - 2 months ago

Zevra Therapeutics, Inc. (ZVRA) Q2 2025 Earnings Call Transcript


Zevra Therapeutics, Inc. (ZVRA) Q1 2025 Earnings Call Transcript

May 13, 2025, 10:45 PM EDT - 5 months ago

Zevra Therapeutics, Inc. (ZVRA) Q1 2025 Earnings Call Transcript


Zevra Therapeutics Files Preliminary Proxy

Mar 31, 2025, 4:12 PM EDT - 7 months ago

Zevra Therapeutics Files Preliminary Proxy


Zevra Therapeutics, Inc. (ZVRA) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 8:16 PM EDT - 8 months ago

Zevra Therapeutics, Inc. (ZVRA) Q4 2024 Earnings Call Transcript


Zevra to Participate at Upcoming Investor Conferences

Feb 24, 2025, 4:02 PM EST - 8 months ago

Zevra to Participate at Upcoming Investor Conferences


Zevra Therapeutics Announces Organizational Changes

Dec 6, 2024, 5:00 PM EST - 11 months ago

Zevra Therapeutics Announces Organizational Changes


US FDA approves Zevra's genetic disorder treatment

Sep 20, 2024, 10:14 AM EDT - 1 year ago

US FDA approves Zevra's genetic disorder treatment


Zevra Therapeutics Expands Executive Leadership Team

Jun 25, 2024, 7:30 AM EDT - 1 year ago

Zevra Therapeutics Expands Executive Leadership Team


HuntingHighAndLow
HuntingHighAndLow Oct. 25 at 9:38 PM
$ZVRA The table below comes from the linked healthcare economics report that looks at FDA-approved drugs launched between 2022–24. The discrepancy between prescriptions written and first-time dispensed owes mainly to payer non-coverage and “utilization” delays such as prior authorization and step therapy. “On average, only 29% of total dispensed commercial new-to-brand prescriptions were ultimately successfully filled overall.” While not a marketing report, additional tables and figures feature data collected by IQVIA that I’ve seen nowhere else. https://icer.org/wp-content/uploads/2025/10/ICER_2025_Launch-Price-and-Access-Final-Report_For-Publication.pdf
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 25 at 5:49 PM
Enter: $ZVRA Calls Strike Price: $11 Expiry Date: NOV 21 2025 Buy in Price: $1.20 - $2.00 Sell Price: $1.70 Profit : +42% (Turn every $1 into $1.42) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
KemPharm_rocks
KemPharm_rocks Oct. 25 at 3:47 PM
$ZVRA Here’s my point, just in case you missed my sarcasm. Go buy your shares, sit down, and read a book. Many of us have been waiting here for over five years. And I do not say that to impress you, but to impress upon you, that it is time to relax about Zevra. The handwriting is on the wall.
2 · Reply
KemPharm_rocks
KemPharm_rocks Oct. 25 at 3:35 PM
$ZVRA “Oh, my little margin account!” Waaaa 😭! “Oh, my little call options!” Waaaa 😭! “Oh, my little put options!” Waaaa 😭! “Oh, my little warrants!” Waaaa 😭! STFU. We don’t give a flying rats ass about the shares you are swinging around with day-trading either. Wake the F up, nobody here wants to hear about it. Go complain to your therapist, see what they have to tell you.
0 · Reply
KemPharm_rocks
KemPharm_rocks Oct. 25 at 3:30 PM
$ZVRA One fortnight, which is the Old English term , meaning fourteen nights. So all you complaining weenies out there, need to keep your panties and poopie diapers on for one more fortnight. If you can’t handle that, then you do not belong here with the big boys, the little play pin is down the hallway on your right. Now GTF out of my house! 🤭
0 · Reply
jemer
jemer Oct. 25 at 3:27 PM
$ZVRA Keep reading over and over again that Migulstat/Miplyffa is the primary standard of care and Aqneursa is secondary. This Facebook Post is from NPC Awareness page. When she talks about Arimoclomol not being FDA approved, she must mean that it wasnt approved when her child was 1st diagnosed with NPC.
1 · Reply
KemPharm_rocks
KemPharm_rocks Oct. 25 at 3:18 PM
$ZVRA 10 Business Days!!! Let’s start the countdown. The world 🌎 will FINALLY have their proof, in back & white, that Zevra is among the few, the proud, and PROFITABLE small-cap biotech companies out there. No more of this “cash-runway till…” crap! Cash runway FOREVER!!!
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 25 at 2:14 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ZVRA Current Share Price: $10.70 Contracts: $ZVRA December 18, 2026 $12 Calls Scale in: $2.88- $3.52 Scale out: $4.48-$5.76 Can Easily Capture: 60% ROI Blended DTE: 421 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
KakashiFlux
KakashiFlux Oct. 25 at 1:40 AM
0 · Reply
WaynD01
WaynD01 Oct. 24 at 11:58 PM
$ZVRA To every one’s surprise the short interest is down by 1M ahares. If you were following the short interest history very closely you will realize that it was an unprofitable trade for them. They were shorting this in single digits all the time and it was in 2 digits in all the reporting period . So why they decided to cover for a loss? 1) Great Q3 earnings, 2) Buyout 3) scared of a short squeeze, etc Also we see they have changed their MO of waking down the price. All these makes me more optimistic.
0 · Reply
KemPharm_rocks
KemPharm_rocks Oct. 24 at 11:40 PM
$ZVRA You are correct, it is out already: Key Insights from the October 15, 2025 Report: • Shares Shorted: Down to 7,991,725 from 9,067,314 as of September 30, 2025—a -11.86% decrease (about 1.08 million fewer shares shorted). • % of Float Shorted: Assuming ZVRA’s float remains ~46.8 million shares (based on prior data), this equates to ~17.07% of float (slightly down from ~19.38% previously). • Days to Cover Estimate: The 2.3% of avg. daily volume suggests ~2.3 days to cover (a low/moderate level, down from ~3.1 days previously).
0 · Reply
gc358
gc358 Oct. 24 at 9:04 PM
$ZVRA well, shock the st*t out of me. Short interest dropped to 7,991,725 for the period ending 10/15. Drop of 1,075,589. I expected an increase. Looks like the may have started covering from record levels. Too bad no squeeze yet.
0 · Reply
RaySan
RaySan Oct. 24 at 7:21 PM
$ZVRA Volume dried up. Why? Price stagnating while my other stocks are happy today. Why? Make it make sense.
2 · Reply
Jhh3796
Jhh3796 Oct. 24 at 6:22 PM
$ZVRA Have we had any updates on the litigation? That I believe is the main thing holding us back from a better price and acquisition.
2 · Reply
MikeyNJ
MikeyNJ Oct. 24 at 4:00 PM
$ZVRA Open interest on the November $13 calls is 1167 contracts. 1047 have traded today at the bid price meaning the position was closed out or they were sold to open to bring in income. Won't know until updated open interest is reported tomorrow. Regardless, those contracts control 100,000 shares which represents approximately 50% of today's total volume which is very low. Probably the reason for the price not getting any traction in an up market. But, it's only noise in the short term. Stock price remains cheap. The saga continues.
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 24 at 3:57 PM
Enter: $ZVRA NOV 21 2025 $11 CALLS Buy in Price: $1.20 - $2.00 Take Profit: $2.30 Stop Bleeding: $1.06 ROI Potential: 92% https://moneygroup.us/
0 · Reply
DevAd
DevAd Oct. 24 at 2:52 PM
0 · Reply
KemPharm_rocks
KemPharm_rocks Oct. 24 at 2:23 PM
$ZVRA Not that it makes any difference, but consumer interest in Azstarys seems to be on a slow rise again (5-10% year over year). It maintains a niche of increasing interest in terms of a non-amphetamine option, and has a 7.4/10 satisfaction rating on http://Drugs.com and http://GoodRx.com still offers a nice discount.
2 · Reply
Pnbs44
Pnbs44 Oct. 24 at 1:58 PM
$ZVRA Normally algos would be eating us alive and tanking the SP with such low volume. Interesting how SP seems to be holding steady. Imagine how we'll do when we actually have good news to report.
4 · Reply
intowits
intowits Oct. 24 at 1:18 PM
0 · Reply
KemPharm_rocks
KemPharm_rocks Oct. 24 at 11:34 AM
$ZVRA I may have goofed on this original post, as I later learned that it was a 90-day wait-period for the LoQ, which would make this coming Monday the target date 🎯. That said, it is not considered a material event, and Neil is under no obligation to share anything about its content. If the LoQ is benign, and sharing such details suits his agenda, then he may mention some highlights on the Q3 EC. If, however, sharing would not suit his agenda, rest assured that any analyst worth their salt, will at least be asking about the LoQ, during the question and answer period of the EC. At that point, Neil will be hard-pressed to do a full obfuscation. He will need to say something about it. But since Neil is the CEO, he will have to paint it in a positive light, even if the EMA’s response was cataclysmically negative. Time will tell, but I think we can safely rule out a pessimistic response from the EMA.
0 · Reply
Cube_CH
Cube_CH Oct. 24 at 10:45 AM
0 · Reply